Dean Li, Executive VP & President, MRL of Merck & Co Inc (MRK, Financial), has sold 14,702 shares of the company on February 9, 2024, according to a recent SEC Filing. The transaction was executed at an average price of $125.5 per share, resulting in a total value of $1,845,151.
Merck & Co Inc is a global healthcare company that provides prescription medicines, vaccines, biologic therapies, and animal health products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company's primary focus is on the development and marketing of products related to human health and well-being.
Over the past year, the insider has sold a total of 14,702 shares and has not made any purchases. The recent sale by Dean Li is part of a broader trend observed within the company's insider transaction history.
Insider Trends
The insider transaction history for Merck & Co Inc shows a pattern of insider activity. In the past year, there has been only 1 insider buy, contrasted with 18 insider sells, indicating a general disposition towards selling among insiders at the company.
Valuation
On the day of the insider's recent transaction, shares of Merck & Co Inc were trading at $125.5, giving the company a market capitalization of $317,614.452 billion. The price-earnings ratio of the stock stands at 895.29, which is significantly above both the industry median of 22.18 and the company's historical median price-earnings ratio.
The stock's price-to-GF-Value ratio is 1.16, with a GF Value of $107.77, suggesting that Merck & Co Inc is currently Modestly Overvalued according to GuruFocus's valuation model.
The GF Value is calculated considering historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
